News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase II
AM-Pharma Completes Patient Recruitment Of Recombinant Human Alkaline Phosphatase (recAP) Phase II Trial In Acute Kidney Injury 5/22/2017
Xynomic Pharma And UCSF Entered Strategic Partnership In Conducting A Phase II/III Trial Of Abexinostat Against Renal Cell Carcinoma 5/22/2017
Myovant (MYOV) Announces Presentation Of Positive Phase II Data For Relugolix In Women With Endometriosis-Associated Pain At The World Congress On Endometriosis 5/22/2017
Arbutus Biopharma (ABUS) Presents HBV Drug Combination Studies At ICAR 5/22/2017
6 (Plus 2!) Most Notable ASCO Abstracts So Far 5/22/2017
Shire (SHPG)'s Hemophilia A Drug Flunks Tiny Phase I Trial 5/22/2017
Versartis (VSAR) Presents 3-Year Somavaratan Safety And Efficacy Data And Pediatric Program Baseline Demographics At The 19th European Congress Of Endocrinology 5/22/2017
Anavex (AVXL) Reports New Data For ANAVEX 2-73 In Neurodevelopmental Disorders Including Angelman Syndrome: Data Presented At Antiepileptic Drug Trials XIV 2017 Conference 5/22/2017
Merck & Co. (MRK) Announces Presentation Of Phase II Results For MK-7264, An Investigational, P2X3 Receptor Antagonist, Being Evaluated For The Treatment Of Chronic Cough 5/22/2017
5 Biotechs Releasing Highly-Anticipated Data at ASCO 5/19/2017
Revance (RVNC) Announces Positive Top-Line 24-Week Duration Of Effect Results In All Three Cohorts In RT002 Injectable Phase II Cervical Dystonia Trial 5/19/2017
Nordic Nanovector Release: Safety Review Committee Approves The Continued Evaluation Of The 20 Mbq/Kg Betalutin With 100 Mg/M2 Lilotomab Regimen In Phase ll Cohort In NHL 5/19/2017
Aldeyra (ALDX) Presents Noninfectious Anterior Uveitis Phase II Clinical Trial Data At Association for Research in Vision & Ophthalmology 2017 Annual Meeting 5/19/2017
Polyphor Announces Successful End Of Phase II Meeting With FDA For Murepavadin In Nosocomial Pneumonia 5/19/2017
Soligenix (SNGX) Announces Publication Of Its Phase II Long-term Follow-up Results Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 5/18/2017
Myovant (MYOV) Announces Upcoming Presentations Of Relugolix Data From Phase II Trial In Women With Endometriosis-Associated Pain 5/18/2017
Astellas (ALPMY) Announces Oncology Portfolio Updates 5/18/2017
CASI Pharma (CASI) Announces Abstract On ENMD-2076 In Clear Cell Ovarian Cancer 5/18/2017
The Lancet Publishes Phase ll Results From Shire (SHPG)'s Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates In Patients With Moderate-To-Severe Ulcerative Colitis 5/18/2017
Incyte (INCY) Release: New Data For Presentation At ASCO 2017 Reinforce Clinical Profile Of Epacadostat In Combination With Keytruda® (Pembrolizumab) 5/18/2017
ArQule (ARQL) To Present Clinical Data At The 2017 ASCO Annual Meeting 5/18/2017
Symic Biomedical Announces Results From MODIFY-OA Trial Of SB-061 For The Treatment Of Osteoarthritis Of The Knee 5/18/2017
Cellceutix (CTIX) Completes Patient Enrollment Of Final Cohort In Phase II Trial Of Brilacidin For Inflammatory Bowel Disease; Topline Results Anticipated In July 5/18/2017
Epizyme (EPZM) Announces Path Toward Tazemetostat Registration In Epithelioid Sarcoma And Reports New Clinical Data To Be Presented At ASCO 5/18/2017
Data From Prima Biomed (PRR.AX) AIPAC Clinical Trial To Be Presented At 2017 ASCO Conference 5/18/2017
Nanobiotix Announces First Positive Human Data Showing That NBTXR3 Could Become A Backbone In Immuno-Oncology 5/18/2017
NeuralStem Reports Last Subject Out In Phase II Trial Of NSI-189 For Major Depressive Disorder 5/18/2017
Syndax Announces Results From Phase II ENCORE 601 Trial Of Entinostat In Combination With KEYTRUDA (Pembrolizumab) For The Treatment Of Advanced Melanoma 5/18/2017
Celldex (CLDX) To Present Clinical Results At 2017 ASCO Annual Meeting 5/18/2017
Merus (MRUS) Announces Promising Results From MCLA-128 Phase I/II Study In Metastatic Breast Cancer 5/18/2017
GlycoMimetics (GLYC) Stock Takes Off on Positive Phase II Leukemia Data, Breakthrough Tag 5/18/2017
FDA Slaps Clinical Hold on Concert Pharma (CNCE)'s Hair Loss Drug 5/18/2017
Eiger Biopharma Announces Results Demonstrating Benefit Of Ubenimex And Leukotriene B4 (LTB4) Modulation In Experimental Lymphedema 5/17/2017
Rhythm Expands Phase II Clinical Trials Of Setmelanotide To The Treatment Of Bardet-Biedl Syndrome Obesity 5/17/2017
Omeros (OMER) Announces Completion Of IgA Nephropathy Cohort In OMS721 Phase II Clinical Trial 5/17/2017
FDA Grants Bayer (BAY) Priority Review For Investigational Compound Copanlisib In Follicular Lymphoma 5/17/2017
Viamet Data For VT-1161 And VT-1598 To Be Presented At American Society for Microbiology’s ASM Microbe 2017 Conference 5/17/2017
CytoDyn (CYDY) Treats First Patient With PRO 140 In Phase II Trial For Graft Versus Host Disease 5/17/2017
NOXXON Pharma AG Announces Collaboration With National Center For Tumor Diseases In Heidelberg For Nox-A12/Keytruda Phase I/II Combination Trial 5/16/2017
Inventiva Announces Positive Results Of 12 Month Primate Toxicity Study With IVA337 5/16/2017
TG Therapeutics (TGTX): Significant Near-Term Catalysts For 2017 5/16/2017
Cara Therapeutics (CARA): A Look At The Next Catalyst—Osteoarthritis 5/16/2017
NLS Pharma Announces Phase ll Study Of NLS-1 (Mazindol) In Adult ADHD Patients Has Met All Primary And Secondary Endpoints 5/16/2017
Sangamo (SGMO) Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy 5/16/2017
Galapagos (GLPG.BR) Release: Seven Abstracts On Filgotinib Accepted By EULAR 2017 5/16/2017
The FDA Calls Ignyta (RXDX)'s Tumor Drug Entrectinib A Breakthrough 5/15/2017
Ignyta (RXDX) Granted Breakthrough Therapy Designation For Entrectinib By U.S. FDA 5/15/2017
Eiger Biopharma Completes Enrollment Of Phase II LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension 5/15/2017
Biohaven (BHVN)'s Trigriluzole Receives Fast Track Designation From U.S. FDA 5/15/2017
Cytokinetics (CYTK) Announces Orphan Drug Designation For CK-2127107 For The Treatment Of Spinal Muscular Atrophy 5/15/2017
Cold Genesys, Inc. Announces Clinical Results At American Urological Association Annual Meeting 2017 5/15/2017
Spring Bank Pharmaceuticals, Inc. Announces The Data Safety Monitoring Board Approves Dose Escalation Of SB 9200 For The Second Cohort Of The Phase IIa Segment Of The ACHIEVE Trial, A Global Phase II Clinical Trial For Chronic Hepatitis B Virus (HBV) 5/15/2017
Minerva Biotechnologies Corporation Announces Outcome Of End-Of-Phase II Meeting With FDA 5/15/2017
Summit Therapeutics Completes Enrollment Of Phaseout DMD, A Phase II Clinical Trial Of Ezutromid In Patients With DMD 5/15/2017
Alexion (ALXN) Release: Long-Term Data Confirm Benefits Of Treatment With Strensiq (Asfotase Alfa) In Adolescents And Adults With Hypophosphatasia (HPP) Through Five Years 5/15/2017
Resverlogix (RVX.TO) Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial 5/15/2017
Sangamo (SGMO) Presents Recent Developments From Research And Clinical Programs At Annual Meeting Of The American Society Of Gene & Cell Therapy 5/15/2017
MMJ PhytoTech Receives Approval To Conduct Phase II Clinical Trial For Treatment Of Multiple Sclerosis Symptoms 5/15/2017
Formation Biologics Announces Dosing Of First Patient In A Phase I/Ila Trial Of AVID100, Closing Of Series B Financing, And Appointment Of Dr. Anthony Tolcher To Its Board Of Directors 5/15/2017
SoCal's Capricor to Reduce Workforce and Shift Focus After Discouraging Trial Results 5/12/2017
Antibe Therapeutics (ATE.V) Engages Topstone Research And Appoints Dr Francis Chan As Key Advisor For Phase II Clinical Trial Of ATB-346 5/12/2017
4 Biotechs That Could Release Stock-Shattering Data Soon 5/11/2017
GTx, Inc. (GTXI) Announces Acceptance Of An Abstract On Preliminary Results From Phase II Clinical Trial In Women With Stress Urinary Incontinence At The International Continence Society Annual Meeting 5/11/2017
Synthetic Biologics (SYN) Release: SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation From FDA For Prevention Of Clostridium Difficile Infection 5/11/2017
Rhythm Receives Expanded FDA Breakthrough Therapy Designation For Setmelanotide For Rare Genetic Disorders Of Obesity 5/11/2017
Xencor's Lead Drug Candidate, Xmab5871, Receives Orphan Drug Designation From FDA For Treatment Of Igg4-Related Disease 5/11/2017
New MRI Data From Asterias Biotherapeutics' Ongoing SCiStar Clinical Study Indicates AST-OPC1 Cells Prevent Formation Of Damaging Lesion Cavities In Patients Suffering Severe Spinal Cord Injury 5/11/2017
Milestone Pharma Announces Etripamil Phase II Clinical Program Success For The Treatment Of Paroxysmal Supraventricular Tachycardia 5/11/2017
Peloton Therapeutics Initiates Patient Dosing In Phase II Study Of PT2385 For Von Hippel-Lindau Disease-Associated Kidney Cancer 5/11/2017
Biophytis: First Patient-In In The United States And Opening Of 2 Clinical Centers For The SARA-OBS Study On Sarcopenia 5/11/2017
FDA Grants Fast Track Designation For Celyad’s Ischemic Heart Failure Therapy, C-Cure 5/11/2017
Aevi Genomic Medicine (GNMX) Announces Plans To Initiate Phase II Clinical Trial To Confirm Genetic Responders To AEVI-001 And First Quarter 2017 Operating Results 5/11/2017
Agilis Biotherapeutics Announces Presentation Of Data From Phase I/II Trial For Treatment Of AADC Deficiency 5/10/2017
Ironwood (IRWD) Presents Data Further Elucidating Linaclotide’s Effect On Pain At Digestive Disease Week 2017 5/10/2017
Cellceutix (CTIX) Provides Corporate Update; Significant Milestones Ahead As Multiple Mid-Phase Clinical Trials Set To Conclude 5/10/2017
Catalyst Pharma (CPRX) Announces Poster Presentation Of Musk-MG Clinical Data At The 13th International Conference On Myasthenia Gravis And Related Disorders 5/10/2017
Catastrophic Year for Bay Area's OncoMed (OMED) Continues as Lead Drug Comes Crashing Down in Phase II Study 5/9/2017
3 Cancer Biotechs to Watch at ASCO 5/9/2017
BioTime (BTX) Announces New Positive Data From OpRegen Trial In Dry-AMD 5/9/2017
PureTech Announces Initiation Of Phase IIb mTORC1 Inhibitors Study In Elderly Patients At Increased Risk Of Respiratory Tract Infections 5/9/2017
Oncoquest Announces Enrollment Of First Patient In Phase I/II Clinical Study Using Combination Of Oregovomab With Checkpoint Inhibitor Nivolumab In Recurrent Ovarian Cancer 5/9/2017
Santalis Enrolls First U.S. Subject Into A Phase II Clinical Study Of Mild To Moderate Atopic Dermatitis 5/9/2017
AiCuris Initiates U.S. Clinical Phase II Trial With Oral Pritelivir For The Treatment Of HSV Infections In Immunocompromised Adults 5/9/2017
AbbVie (ABBV) Announces Positive Phase II Study Results For Upadacitinib (ABT-494), An Investigational JAK1-Selective Inhibitor, In Crohn's Disease 5/9/2017
RegeneRx Biopharmaceuticals, Inc. (RGRX) JV Presents Results Of Phase IIb/III (ARISE-1) Dry Eye Trial At Association for Research in Vision & Ophthalmology 2017 5/9/2017
GrayBug's Potential Once-Per-Year AMD Treatment Data Presented At Association for Research in Vision & Ophthalmology 2017 5/9/2017
Eyevensys Announces The First-In-Human Treatment With Its GroundBreaking EyeCET ElectroTransfection Technology For Eye Diseases 5/9/2017
Myovant (MYOV) Announces Presentation Of Positive Phase II Data For Relugolix In Women With Heavy Menstrual Bleeding And Uterine Fibroids At The Annual Meeting Of The American Congress Of Obstetricians And Gynecologists 5/8/2017
Oncolytics Biotech (ONC.TO) Announces FDA Fast Track Designation For REOLYSIN In Metastatic Breast Cancer 5/8/2017
Acceleron Pharma Release: Luspatercept Phase II Data Presented At The 14th International Symposium On Myelodysplastic Syndromes 5/8/2017
DelMar Pharma Presents New Mechanism Of Action Data For Its Lead Agent VAL-083 In Temozolomide-Resistant Glioblastoma Multiforme (GBM) At The World Federation Of Neuro-Oncology Societies (WFNOS) 5/8/2017
Rasna Therapeutics (ATVM) Advances Development Of A Novel Treatment For NPM1-Mutated Acute Myeloid Leukemia 5/8/2017
Syros Pharma Presents New Insights On Mechanism Of Action Of SY-1425, Its First-In-Class Selective RARa Agonist, In Oral Plenary Session At AACR Hematologic Malignancies Conferencee 5/8/2017
Takeda (TKPYY) Announces Publication Of ALUNBRIG (brigatinib) Pivotal Phase II ALTA Clinical Trial Data In Journal Of Clinical Oncology 5/8/2017
PharmaCyte (PMCB) Updates IND Submission Process In Interview With Facet Life Sciences 5/8/2017
Axsome (AXSM) Receives FDA Fast Track Designation For AXS-05 For Alzheimer’s Disease Agitation 5/8/2017
Galapagos (GLPG.BR) Presents Three Posters On Filgotinib In Crohn's Disease At DDW 2017 5/8/2017
Is This Fake News? Neurotrope (NTRP) Alzheimer's Release Takes Weird Spin 5/5/2017
4 Biotechs That Could Explode Or Crash In May 5/5/2017
First Patient Enrolled In Mallinckrodt (MNK) Phase II Trial Of StrataGraft Regenerative Skin Tissue 5/5/2017
Syros Pharma Reveals Discovery Of Novel Drug Targets For Triple Negative Breast Cancer 5/5/2017
GENFIT (ALGFT): First Patient Enrolled In A Phase II Trial Recruiting Adults With Primary Biliary Cholangitis (PBC), A Rare Liver Disease 5/5/2017
GENFIT (ALGFT): First Patient Enrolled In A Phase II Trial Recruiting Adults With Primary Biliary Cholangitis (PBC), A Rare Liver Disease 5/5/2017
A New Weapon In The War Against Opioid Abuse? 5/4/2017
BioPharmX Reports Positive Topline Results Of BPX-01 Topical Minocycline For Acne 5/4/2017
Apricus Biosciences (APRI) Announces The Initiation Of Vitaros Drug-Device Human Factors Study 5/4/2017
Poxel (POXEL.PA) Rockets After Diabetes Med Hits Goals In Mid-Stage Study 5/4/2017
Neovacs To Present Clinical Development Update On IFNa Kinoid in Dermatomyositis 5/4/2017
Genocea (GNCA) Reports First Quarter 2017 Financial Results And Positive Clinical Developments On Lead Candidate GEN-003 In Genital Herpes 5/4/2017
Argenx Reaches 50% Enrollment In Phase II Clinical Trial Of ARGX-113 In Myasthenia Gravis 5/4/2017
Oncoceutics Release: Research Publications Provide Rationale For ONC201 Trials In Breast Cancer 5/4/2017
Rigontec GmbH Starts First-In-Human, Phase I/II Trial Of RIG-I Agonist RGT100 And Appoints Eugen Leo As Chief Medical Officer 5/3/2017
GenKyoTex S.A. Announces FDA Approval Of IND For Phase II Trial Of GKT831 In Patients With Primary Biliary Cholangitis 5/3/2017
Glaukos Completes Patient Enrollment In Phase II Clinical Trial For iDose Travoprost Intraocular Implant In Glaucoma Patients 5/3/2017
Verastem (VSTM) Announces Long Term Follow-Up Data From The DYNAMO Study Selected For Oral Presentation At The 14th International Conference On Malignant Lymphoma 5/3/2017
Can-Fite BioPharma (CFBI)'s Liver Protective Drug Namodenoson Enters Phase II Trial For Treatment Of NAFLD/NASH 5/3/2017
Bonti Announces Hot Topics Presentation Of Phase IIa Interim Clinical Data At The Aesthetic Meeting 2017 5/3/2017
EndoLogic Announces Scheduling Of Pre-IND Meeting With FDA To Discuss Renzapride In Diabetic Gastroparesis 5/3/2017
jCyte Receives Regenerative Medicine Advanced Therapy Designation 5/2/2017
Concert Pharma (CNCE) Initiates CTP-543 Phase II Trial In Alopecia Areata 5/2/2017
Stealth Biotherapeutics Initiates Phase I/II Trial Of SBT-20 In Patients With Early Stage Huntington's Disease 5/2/2017
Altor BioScience Corporation Announces FDA Fast Track Designation For Lead Candidate ALT-803 In Patients With Non-Muscle Invasive Bladder Cancer 5/2/2017
Prolong Pharmaceuticals Release: New Research Suggests SANGUINATE Reduces The Number Of Sickled Red Blood Cells In Patients With Vaso-Occlusive Crisis 5/2/2017
Abivax (ABVX.PA) Stock More Than Doubles On Mid-Stage HIV Data 5/2/2017
Phase II CoDIFy Trial Results Published In Lancet Infectious Diseases With Data Showing Summit Therapeutics’s Ridinilazole Achieved Statistical Superiority Over Vancomycin In The Treatment Of C. Difficile Infection 5/2/2017
First Ever Evidence Of Treatment-Induced Reduction In HIV Reservoirs:Abx464, Abivax (ABVX.PA) Lead Drug Candidate, Impacted Hiv Blood Reservoir In A Phase IIa Clinical Trial (Abx464-004) 5/2/2017
Summit Therapeutics: Phase II CoDIFy Trial Results Published In Lancet Infectious Diseases 5/2/2017
Neurotrope (NTRP) Craters As Alzheimer's Drug Fails To Impress In Mid-Stage Study 5/1/2017
Revance (RVNC) Provides Update On Phase II Program For RT002 Injectable In The Management Of Plantar Fasciitis 5/1/2017
Cantex Pharmaceuticals Announces Initiation Of Phase II Clinical Development For CX-02 In Recurrent Glioblastoma 5/1/2017
Tarveda To Present On Lead Intracellular Targeting Pentarin PEN-866 At 2017 American Association Of Pharmaceutical Scientists National Biotechnology Conference 5/1/2017
Xenetic Biosciences Presents Case Study Of PolyXen Platform Technology At The 13th Annual Protein Engineering Summit (PEGS) Boston 5/1/2017
Syros Pharma Participates In International Symposium To Support MDS Foundation’s Efforts To Raise Awareness Of Novel Therapies In Development For MDS 5/1/2017
Alder Biopharma Presents Positive Phase IIb Study Data For Eptinezumab At 69th Annual American Academy of Neurology Meeting 5/1/2017
Triphase Accelerator Reports Completion Of Initial Regulatory Interactions With FDA And Health Canada For TRPH-222 For The Treatment Of Lymphoma 5/1/2017
Living Cell Tech Release: Treatment Completed For All Patients In Parkinson’s Trial 5/1/2017
Phase II CoDIFy Trial Results Published In Lancet Infectious Diseases With Data Showing Summit Therapeutics’s Ridinilazole Achieved Statistical Superiority Over Vancomycin In The Treatment Of C. Difficile Infection 5/1/2017
Nordic Nanovector Release: Updated Results From Phase I/II Trial Of Betalutin In NHL Accepted For Presentation At The International Conference On Malignant Lymphoma In June 4/28/2017
TG Therapeutics (TGTX) Announces Preliminary Results From Ongoing Phase II Study Of TG-1101 (Ublituximab) In Patients With Multiple Sclerosis At The American Academy of Neurology 4/28/2017
Flexion (FLXN) Highlights Two Clinical Data Presentations At The Osteoarthritis Research Society International 2017 World Congress 4/28/2017
Neurotrope To Release Results From Phase II Clinical Trial In Moderate To Severe Alzheimer’s Disease On May 1, 2017 4/28/2017
Aspyrian Therapeutics Announces The Presentation Of Clinical Data Of Its Investigational Therapy Rm-1929 Demonstrating Significant Anti-Cancer Response In Recurrent Head And Neck Cancer Patients Who Have Failed All Existing Treatment Options 4/28/2017
Braeburn Pharma Achieves Primary Endpoint In Pivotal Phase II/III Study Of BB0817, Risperidone 6-Month Implant For Treatment Of Schizophrenia 4/27/2017
Pfizer (PFE)’s Next-Generation ALK/ROS1 Inhibitor, Lorlatinib, Granted Breakthrough Therapy Designation From FDA For ALK-Positive Metastatic Non-Small Cell Lung Cancer 4/27/2017
Bonti Announces Inaugural Presentation Of Phase IIa Clinical Data For Its Lead Product EB-001 4/27/2017
Syndax Announces Expansion Of Immuno-Oncology Collaboration Evaluating Entinostat In Combination With KEYTRUDA (Pembrolizumab) For The Treatment Of Colorectal Cancer 4/27/2017
Akari Therapeutics Announces Edison’s Withdrawal Of Edison Report Titled “Akari’s Coversin Matches Soliris In Phase II” 4/27/2017
PIQUR Therapeutics AG Receives EMA Orphan Drug Designation For PQR309 In Diffuse Large B-Cell Lymphoma 4/27/2017
Wilson Therapeutics Presents Promising Neurological Phase 2 Data For WTX101 At American Academy of Neurology Meeting 4/26/2017
Galapagos (GLPG.BR) Announces New Phase II Proof-Of-Concept Study With Filgotinib In Cutaneous Lupus Erythematosus 4/26/2017
Gilead (GILD)'s $600 Million NASH Deal Finally Bears Fruit 4/26/2017
Powered By CIRM Grant, jCyte Launches New Clinical Trial 4/26/2017
Ra Pharma (RARX) Initiates Dosing Of RA101495 In PNH Patients 4/26/2017
Asterias Biotherapeutics Announces Publication Of Positive Phase II Data On AST-VAC1 For The Treatment Of Acute Myeloid Leukemia (AML) In 'Cancer' 4/26/2017
ARCA biopharma Announces 200th Patient Randomized Into The GENETIC-AF Seamless Design Phase IIB/III Clinical Trial 4/26/2017
New Data At American Academy of Neurology Reinforce Clinical Benefit Of Genentech (RHHBY)'s OCREVUS (Ocrelizumab) For Relapsing And Primary Progressive Multiple Sclerosis 4/26/2017
FDA Clears Flex's FLX-787 To Commence U.S. Phase II Trial In ALS Under IND 4/26/2017
Galapagos (GLPG.BR) Announces New Phase II Proof-Of-Concept Study With Filgotinib In Cutaneous Lupus Erythematosus 4/26/2017
Finally! Novartis AG (NVS) To Release Long-Awaited Juliet CAR-T Data In June 4/25/2017
ASLAN Initiates Global Pivotal Study For Varlitinib In Biliary Tract Cancer 4/25/2017
Blueberry Therapeutics Commence Phase I/II Clinical Trial Of Lead Product BB2603 4/25/2017
Capricor Therapeutics, Inc. Announces Positive Six-Month Results From The Randomized Phase I/II HOPE Clinical Trial In Duchenne Muscular Dystrophy 4/25/2017
Jazz Pharma (JAZZ) Announces Positive Results From The Phase II/III EXPRESS Study Of Xyrem In Pediatric Patients With Narcolepsy With Cataplexy 4/25/2017
Asterias Biotherapeutics Announces Data Monitoring Committee Unanimously Recommends Continuation Of Scistar Phase I/IIa Clinical Trial Of AST-OPC1 For Cervical Spinal Cord Injury 4/25/2017
Vyome Completes Enrollment For Proof Of Concept Clinical Study Of VB 1953 In Patients With Moderate To Severe Acne 4/25/2017
Eight Data Presentations At ECCMID Showcase The Broad Applicability Of SCYNEXIS, Inc. (SCYX)’ Lead Anti-Infective Candidate SCY-078 4/25/2017
Kalytera Therapeutics Identifies Sites For Planned Gvhd Clinical Trials; Company’s Research Gains Support At EBMT 2017 4/25/2017
Epizyme (EPZM) Announces Tazemetostat Fast Track Designation For Follicular Lymphoma And Plenary Session On Phase II NHL Data At ICML 4/25/2017
Top 15 R&D Spenders In The World For 2017 4/24/2017
Tiziana Life Sciences Plc Announces Approval Of A Phase II Clinical Trial Protocol For Milciclib In Patients With Hepatocellular Carcinoma 4/24/2017
NGM Announces NGM282 Dramatically Reduced Liver Fat And Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) In Phase II Trial 4/24/2017
RedHill Biopharma (RDHL) Announces Enrollment Of Last Patient In The BEKINDA Phase II Study For IBS-D 4/24/2017
Shionogi Presents New Clinical And Non-Clinical Data On S-033188, An Investigational Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza, At The 27th European Congress Of Clinical Microbiology And Infectious Diseases 4/24/2017
Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion Recommending Approval Of Opdivo (Nivolumab) For The Treatment Of Patients With Previously Treated Locally Advanced Or Metastatic Urothelial Carcinoma, A Type Of Bladder Cancer 4/24/2017
Medivir (MVRBF) Release: Update On The Development Of Simeprevir As Part Of The Triple Combination With AL-335 And Odalasvir (JNJ-4178) 4/24/2017
Mologen (MOLGF.PK): Positive Subgroup Results Of The Exploratory Phase II IMPULSE Study Of Lefitolimod In Extensive-Disease Small-Cell Lung Cancer (SCLC) 4/24/2017
Merck & Co. (MRK) Announces New Phase II Data On Investigational Triple Combination Therapy MK-3682B For Chronic Hepatitis C 4/24/2017
Gilead (GILD) Announces Scientific Presentations Demonstrating Efficacy Of Harvoni (Ledipasvir/Sofosbuvir) In Special Patient Populations With HCV Infection 4/24/2017
Achillion (ACHN) Announces Additional Phase II Results Including 100% SVR24 For Genotype 1 HCV After 6-Weeks Of Once Daily JNJ-4178 4/24/2017
Arbutus Biopharma (ABUS) Announces ARB-1467 Data Presentation At EASL4/24/2017
Akari Therapeutics Demonstrates Positive Response With Coversin In Ongoing Phase II PNH Trial And In Additional Clinical Targets 4/24/2017
Vaccinex, Inc. Announces Preliminary Data From The SIGNAL Clinical Trial (Investigational Drug VX15/2503 As A Potential Treatment For Huntington’s Disease) 4/24/2017
Bristol-Myers Squibb (BMY)'s NASH Candidate Hits Main Goals In Mid-Stage Study 4/24/2017
Inovio Pharma (INO) Initiates Phase II Efficacy Trial With VGX-3100 For HPV-Related Vulvar Pre-Cancers 4/24/2017
aTyr Pharma Presents Analyses Of Resolaris Phase Ib/II Trial In Patients With Limb Girdle Muscular Dystrophy 2B And Facioscapulohumeral Muscular Dystrophy At The American Academy of Neurology 69th Annual Meeting 4/24/2017
XOMA  (XOMA) Announces Positive Results From Its Phase II Proof-Of-Concept Study Of Prolactin Inhibition 4/24/2017
Wilson Therapeutics Presented Positive Final Phase II Data For WTX101 At EASL Annual Meeting 4/24/2017
aTyr Pharma Announces Promising Top-Line Results From Resolaris Phase Ib/II Clinical Trial in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy 4/24/2017
aTyr Pharma Presents Analyses Of Resolaris Phase Ib/II Trial In Patients With Limb Girdle Muscular Dystrophy 2B And Facioscapulohumeral Muscular Dystrophy At American Academy of Neurology 69th Annual Meeting 4/24/2017
Data Enhances Understanding Of ContraVir’s Complementary Anti-HBV Compounds Tenofovir Exalidex (TXL) And CRV431 4/24/2017
Pfizer (PFE) Receives Positive CHMP Opinion For BESPONSA (Inotuzumab Ozogamicin) For The Treatment Of Relapsed Or Refractory Acute Lymphoblastic Leukemia 4/21/2017
Gilead (GILD) Announces Scientific Presentations Demonstrating Efficacy Of Harvoni (Ledipasvir/Sofosbuvir) In Special Patient Populations With HCV Infection 4/21/2017
Aldeyra (ALDX) Receives Orphan Drug Designation From FDA For ADX-102 In Sjögren-Larsson Syndrome 4/21/2017
Gilead (GILD) Presents Proof-Of-Concept Data For GS-0976 In Nonalcoholic Steatohepatitis (NASH) At The International Liver Congress 2017 4/21/2017
Aurinia (AUPH) Releases Additional 48-Week Data From The AURA-LV Study During Late-Breaking Session At National Kidney Foundation 2017 Spring Clinical Meetings 4/21/2017
Eiger Biopharma Announces Additional Phase II Clinical Trial Results For Lonafarnib At The International Liver Congress 2017 4/21/2017
BeiGene (BGNE) Announces Initiation Of First Pivotal Study In China Of PD-1 Antibody BGB-A317 4/21/2017
Jounce (JNCE) Initiates Phase II Portion Of ICONIC Study Of JTX-2011 In Patients With Advanced Solid Tumors 4/21/2017
Why Former Medivation (MDVN) CEO and a Once-Failed Alzheimer's Drug Could be a Recipe for Disaster for Axovant (AXON) 4/20/2017
NIH Study In The New England Journal of Medicine Shows Novartis AG (NVS) Drug Eltrombopag As First-Line Therapy With Standard Treatment Improves Responses In Severe Aplastic Anemia 4/20/2017